ASXL1 and SETBP1 Mutations and Their Prognostic Contribution in Chronic Myelomonocytic Leukemia: a Two-center Study of 466 Patients

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Apr 4

PMID 24695057

Citations 134

Authors

M M Patnaik

R Itzykson

T L Lasho

O Kosmider

C M Finke

C A Hanson

R A Knudson

R P Ketterling

A Tefferi

E Solary

Affiliations

Soon will be listed here.

Abstract

In a cohort of 466 patients, we sought to clarify the prognostic relevance of ASXL1 and SETBP1 mutations, among others, in World Health Organization-defined chronic myelomonocytic leukemia (CMML) and its added value to the Mayo prognostic model. In univariate analysis, survival was adversely affected by ASXL1 (nonsense and frameshift) but not SETBP1 mutations. In multivariable analysis, ASXL1 mutations, absolute monocyte count >10 × 10(9)/l, hemoglobin <10 g/dl, platelets <100 × 10(9)/l and circulating immature myeloid cells were independently predictive of shortened survival: hazard ratio (95% confidence interval (CI)) values were 1.5 (1.1-2.0), 2.2 (1.6-3.1), 2.0 (1.6-2.6), 1.5 (1.2-1.9) and 2.0 (1.4-2.7), respectively. A regression coefficient-based prognostic model based on these five risk factors delineated high (≥3 risk factors; HR 6.2, 95% CI 3.7-10.4) intermediate-2 (2 risk factors; HR 3.4, 95% CI 2.0-5.6) intermediate-1 (one risk factor; HR 1.9, 95% CI 1.1-3.3) and low (no risk factors) risk categories with median survivals of 16, 31, 59 and 97 months, respectively. Neither ASXL1 nor SETBP1 mutations predicted leukemic transformation. The current study confirms the independent prognostic value of nonsense/frameshift ASXL1 mutations in CMML and signifies its added value to the Mayo prognostic model, as had been shown previously in the French consortium model.

Citing Articles

Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database.

Bangolo A, Amoozgar B, Thapa A, Bajwa W, Nagesh V, Nyzhnyk Y Med Sci (Basel). 2024; 12(4).

PMID: 39584910 PMC: 11587058. DOI: 10.3390/medsci12040060.

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.

Marando L, Csizmar C, Patnaik M Haematologica. 2024; 110(1):22-36.

PMID: 39415698 PMC: 11694134. DOI: 10.3324/haematol.2024.286061.

Distinct clinical profiles and patient outcomes in aCML and CNL.

Sun Y, Wang Q, Zhang Z, Wang Q, Cen J, Zhu M Ann Hematol. 2024; 103(12):5325-5332.

PMID: 39375227 DOI: 10.1007/s00277-024-06032-z.

Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.

Fei F, Jariwala A, Pullarkat S, Loo E, Liu Y, Tizro P Int J Mol Sci. 2024; 25(18).

PMID: 39337700 PMC: 11431978. DOI: 10.3390/ijms251810214.

genotype-based risk stratification outperforms mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.

Csizmar C, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho T Haematologica. 2024; 109(10):3419-3425.

PMID: 38899337 PMC: 11443373. DOI: 10.3324/haematol.2024.285410.

References

Shen Y, Zhu Y, Fan X, Shi J, Wang Q, Yan X . Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011; 118(20):5593-603. DOI: 10.1182/blood-2011-03-343988. View

Vannucchi A, Lasho T, Guglielmelli P, Biamonte F, Pardanani A, Pereira A . Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27(9):1861-9. DOI: 10.1038/leu.2013.119. View

Onida F, Kantarjian H, Smith T, Ball G, Keating M, Estey E . Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99(3):840-9. DOI: 10.1182/blood.v99.3.840. View

Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M . Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19):2428-36. DOI: 10.1200/JCO.2012.47.3314. View

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrozek K . ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011; 118(26):6920-9. PMC: 3245212. DOI: 10.1182/blood-2011-08-368225. View

Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A . Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011; 25(7):1200-2. PMC: 4641450. DOI: 10.1038/leu.2011.58. View

Tefferi A, Guglielmelli P, Lasho T, Rotunno G, Finke C, Mannarelli C . CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014; 28(7):1494-500. DOI: 10.1038/leu.2014.57. View

Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24(6):1128-38. PMC: 3035972. DOI: 10.1038/leu.2010.69. View

10.

Tefferi A, Finke C, Lasho T, Wassie E, Knudson R, Ketterling R . U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2013; 28(2):431-3. DOI: 10.1038/leu.2013.286. View

11.

Lasho T, Jimma T, Finke C, Patnaik M, Hanson C, Ketterling R . SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012; 120(20):4168-71. DOI: 10.1182/blood-2012-05-429696. View

12.

Patnaik M, Parikh S, Hanson C, Tefferi A . Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014; 165(3):273-86. DOI: 10.1111/bjh.12756. View

13.

Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V . ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2012; 27(1):82-91. DOI: 10.1038/leu.2012.262. View

14.

Thol F, Friesen I, Damm F, Yun H, Weissinger E, Krauter J . Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(18):2499-506. DOI: 10.1200/JCO.2010.33.4938. View

15.

Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J . Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia. 2009; 24(2):469-73. DOI: 10.1038/leu.2009.218. View

16.

Patnaik M, Lasho T, Hodnefield J, Knudson R, Ketterling R, Garcia-Manero G . SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2011; 119(2):569-72. PMC: 4916563. DOI: 10.1182/blood-2011-09-377994. View

17.

Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View

18.

Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E . Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2010; 96(3):375-83. PMC: 3046268. DOI: 10.3324/haematol.2010.030957. View

19.

Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C . SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013; 27(9):1852-60. DOI: 10.1038/leu.2013.133. View

20.

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D . ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014; 9(1):e85362. PMC: 3897447. DOI: 10.1371/journal.pone.0085362. View